Research Topics
Species | Paolo BernasconiSummaryAffiliation: University of Pavia Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Clinical relevance of cytogenetics in myelodysplastic syndromesPaolo Bernasconi
Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Fondazione Policlinico San Matteo IRCCS, Pavia, Italy
Ann N Y Acad Sci 1089:395-410. 2006..In addition, chromosome abnormalities are independent prognostic factors predicting overall survival and the likelihood of progression in acute myeloid leukemia...
Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institutionPaolo Bernasconi
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy
Ann Hematol 89:545-51. 2010....- Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institutionP Bernasconi
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Leukemia 19:1424-31. 2005.... - Molecularly targeted therapy in acute myeloid leukemiaPaolo Bernasconi
Department of Blood, Heart and Lung Medical Sciences of the University of Pavia, Italy
Ann N Y Acad Sci 1028:409-22. 2004..All these new data have profound clinical and therapeutic implications and will surely translate into the development of molecules that target specific mutations or signal transduction pathways... - World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromesPaolo Bernasconi
Division of Haematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Br J Haematol 137:193-205. 2007.... - Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a reviewPaolo Bernasconi
Division of Haematology, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Br J Haematol 142:695-708. 2008..In early MDS, stromal and neoplastic cells produce high levels of inhibitory cytokines, whereas in advanced MDS and AML they produce high levels of anti-apoptotic molecules... - Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significancePaolo Bernasconi
Department of Blood, Heart and Lung Medical Sciences, Division of Haematology, Policlinico San Matteo IRCCS, University of Pavia, 27100 Pavia, Italy
Br J Haematol 118:545-9. 2002..3;q32) remains to be demonstrated. However, a transition from MGUS to MM may also occur in patients with normal karyotypes or other abnormalities, suggesting the possibility of distinct pathogenetic pathways... - Molecular genetics of acute myeloid leukemiaPaolo Bernasconi
Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Policlinico San Matteo IRCCS, Pavia, Italy
Ann N Y Acad Sci 963:297-305. 2002..Understanding the action of such genes provides new insights into AML pathogenesis and has led us to envisage new therapeutic options... - ABL1 amplification in T-cell acute lymphoblastic leukemiaPaolo Bernasconi
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi No 5, 27100 Pavia, Italy
Cancer Genet Cytogenet 162:146-50. 2005.... - Blast phase of essential thrombocythemia: A single center studyFrancesco Passamonti
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Am J Hematol 84:641-4. 2009..JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia. The outcome of patients is poor whatever the treatment used... - Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patientsFrancesco Passamonti
M D, Division of Hematology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
Haematologica 93:1645-51. 2008..Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this disorder have a propensity to develop thrombosis, myelofibrosis, and leukemia... - Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision makingLuca Malcovati
Division of Hematology, IRCCS, Policlinico San Matteo, 27100 Pavia, Italy
J Clin Oncol 23:7594-603. 2005..MDS with isolated erythroid lineage dysplasia identifies a subset of truly low-risk patients, for whom a conservative approach is advisable... - Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndromeIrene Dambruoso
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
Cancer Genet 205:285-94. 2012.... - Role of the molecular staging and response in the management of follicular lymphoma patientsLuca Arcaini
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy
Leuk Lymphoma 47:1018-22. 2006..Absence of the bcl-2 rearrangement is related to a better EFS and the achievement of a molecular response in peripheral blood after therapy is associated with a better EFS... - Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesLuca Malcovati
Department of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy
J Clin Oncol 25:3503-10. 2007.... - Leukemic transformation of polycythemia vera: a single center study of 23 patientsFrancesco Passamonti
Division of Hematology, IRCCS San Matteo Polyclinic, University of Pavia, Pavia, Italy
Cancer 104:1032-6. 2005..Acute leukemia (AL) may occur as rare and late event of polycythemia vera (PV)... - Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myelomaAlessandro Corso
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Leuk Lymphoma 51:236-42. 2010..In conclusion, Vel-Dex produces high response rates, improves stem cell collection, and overcomes the need for intensification before autologous transplantation... - Survivin expression in acute leukemias and myelodysplastic syndromesRosangela Invernizzi
Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
Leuk Lymphoma 45:2229-37. 2004..Its abnormal expression also in MDS may play a role in promoting aberrantly increased cell viability and contribute to the altered homeostatic balance between cell growth and cell death... - A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosisFrancesco Passamonti
Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Italy
Blood 111:3383-7. 2008..In conclusion, leukocytosis at diagnosis of PV is a risk factor for evolution in post-PV MF. A dynamic score based on hemoglobin level, and platelet and leukocyte count predicts survival at any time from diagnosis of post-PV MF... - Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institutionPaolo Bernasconi
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
Am J Hematol 88:120-9. 2013..Am. J. Hematol. 88:120-129, 2013. © 2012 Wiley Periodicals, Inc... - Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classificationsClaudia Del Fante
Immuno hematology and Transfusion Service, Apheresis and Cell Therapy Unit, and Scientific Direction and Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Transfusion 52:2007-15. 2012..Chronic graft-versus-host disease (cGVHD) classification has recently been improved by the National Institutes of Health (NIH); patients' stratification with those new criteria has implications for patients' prognosis... - Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphomaMario Lazzarino
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Oncology 68:146-53. 2005..Because of the different mechanisms of action and non-overlapping toxicities, combination of rituximab with chemotherapy is a rational approach... - A further case of myeloproliferative syndrome with reciprocal translocation (8;13)(p11;q12)Rosangela Invernizzi
Medicina Interna ed Oncologia Medica, , IRCCS Policlinico S. Matteo, Pavia, Italy
Haematologica 89:239-41. 2004 
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosisVittorio Rosti
Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Pavia, Italy
PLoS ONE 5:e15277. 2010..Due to inherent performance limitations of ECFCs assay, there is an urgent need to arrive to an acceptable standardization of ECFC assessment...- Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host diseaseAnna A Colombo
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Transplantation 81:1087-92. 2006..This study aims to determine the incidence and outcome of nephrotic syndrome in patients who underwent allogeneic stem cell transplantation in a single center... - Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosisFrancesco Passamonti
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Br J Haematol 116:855-61. 2002..The low cumulative 10-year risk of thrombosis, leukaemia and solid tumours indicates that pipobroman is an adequate treatment for patients with high risk ET...